who had undergone a radical or partial nephrectomy between January 1998 and July 2014. Localized or locally advanced renal cancer patients were included. Patients with compromised nodes, distant metastases or incomplete follow-up were excluded. From a total of 287 patients, 66 were excluded because of lymph node involvement and/or distant metastases at the time of diagnosis, and had incomplete or shorter than 12 months of follow-up. Preoperative imaging included ultrasound, computerized axial tomography, nuclear magnetic resonance and a thorax x-ray. The extracted surgical specimen was evaluated by a single anatomy pathologist (VB). The presence of MVI was defined as the microscopic detection of neoplastic cells that invaded the wall of the microvasculature or the presence of neoplastic emboli in those vessels. The patients were divided according to the presence or lack of MVI. In each group, clinical characteristics (age, gender, presence of clinical manifestations such as lumbar pain, hematuria and a palpable mass) and pathological characteristics (tumor diameter, histological type, pathological staging according to TNM) were evaluated. Histological grade, presence of coagulative necrosis, peripheral fat involvement, and vascular macroscopic involvement in the renal vein or inferior vena cava (IVC) were also noted. The follow-up included both thorax and abdomen computerized axial tomography and complete blood testing every 6 months for the first 3 years and annually thereafter. Metastases-free survival (MFS) was defined as time (in months) from the date of diagnosis to the date of distance metastases and cancer-specific survival (CSS) was defined as time to the date the patient died of disease. The statistical analysis was performed with the SPSS Statistics 17.0. A p <0.05 value was considered significant in all tests carried out. The univariate analysis of variable categories was executed either by Chi-square method or Fischer test when most suitable; continuous variables were calculated according to Student test. The principal objectives of this research, metastases-free survival and cancer-specific survival were evaluated by the Kaplan Meier method and the differences between groups were evaluated with the Log-rank test. Multivariate analysis was performed using the Cox proportional method in order to predict risk factors of metastases and cancer-specific mortality.
rESulTS
The study population analysis included 221 patients of which 78 were female (35%) and 143 were male (65%). The median follow-up period was 40 months (range Distant metastases-free survival at 5 years was 60% for the MVI+ group and 87.8% for the MVI-group (log-Rank test <0.0001) ( Figure 1 ). Cancer-specific survival at 5 years was 75% and 95% for the MVI+ group and MVI-group, respectively. These differences were also statistically significant (log-Rank test 0.0001) (Figure 2 ). When performing the multivariate analysis, we demonstrated that independent predictors for distant metastases include symptomatic tumors (p 0.02), tumor staging ≥pT3 (p 0.04) and tumor size (p 0.01). The multivariate analysis using the Cox proportional method in order to determine risk factors for cancerspecific mortality demonstrated that a tumor size 7 cm or higher (p 0.02) and presence of symptomatic tumors (p 0.05) are independent predictors for death related to renal cancer in this group of patients (Table 2) . Microvascular invasion was not present as an independent predictor for metastases or cancer-specific mortality.
DiScuSSion
Renal cell carcinoma (RCC) has an unpredictable natural history and presents with a wide spectrum of possibilities in its evolution [8, 11, 12, 13] . For this reason, the need to establish predictive prognostic elements is essential in order to identify patients with high risk of recurrence or progression. The tumor staging (TNM), size of the primary tumor, nuclear grade and the presence of sarcomatoid elements have been correlated with the prognosis of renal cancer after nephrectomy [14] [15] [16] [17] .
In the last few years, the importance of MVI as a prognostic factor in renal cell carcinoma has been reason for debate; this has emerged due to the importance of this has proven when defining aggressive tumors in various urological or non-urological malignancies. However, the evidence is currently conflicting when correlating MVI as a predictive factor for metastases and death in renal cancer ( In a recent study, Katz et al., evaluated patients with non-metastatic renal cell carcinoma and demonstrated a strong relation between MVI and adverse tumor characteristics in renal carcinoma in the univariate analysis; nonetheless, there was no statistical significance in the multivariate analysis for the three primary objectives outlined: MFS, CSS and total survival (TS). Only the pathological staging and tumor size remained as independent factors. In addition, they did not objectify correlations when analyzing subgroups of patients according to their stage (T1-T2), nor did they evaluate histological subtypes (clear cells). In the last 5 years, new research has emerged in relation to this topic. Bedke et al., studied 201/747 (26.9%) patients with MVI and showed that it presented as a prognostic factor for poor results in RCC.
The authors recommended a stricter follow-up due to the disease progression and referred this group of patients to adjuvant treatment trials [26] . These findings have clear similarity with our series, where we found that MVI was strongly associated with symptomatic tumors, tumor size, pathological staging and histological grade. Nevertheless, it was not revealed as an independent predictor for metastasis or death by cancer. Finally, the only metaanalysis and systematic review with respect to the topic arises in 2015 and is aimed at an association of MVI with unfavorable pathological characteristics and statistical significance in CSS but it was not when evaluating OS [28] . This present research had some limitations. First of all, the microscopic visual inspection was the method with which MVI was determined, while other studies have used immunohistochemistry in their diagnosis (antibodies such as anti-factor VII or anti-CD34) [21] . It should be pointed out that the routine use of these methods would be justified only if clear evidence in favor of MVI as a prognostic factor existed. Second of all, our series only analyzed non-metastatic renal tumors. The question lies in relation to the effect that MVI could have in patients with metastasis from renal carcinoma. In conclusion, our follow-up was limited to 43 months and it may be possible that for a longer time period, MVI could demonstrate higher statistical significance in multivariate analysis. Based on our data and the conflicting evidence in the literature, MVI seems to have a limited clinical advantage for identifying patients with high-risk of recurrence and death by cancer.
concluSionS
In our series, MVI was associated with unfavorable tumor characteristics. However, MVI does not seem to be an independent predictor for metastases and death in patients with non-metastatic renal cancer.
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However, previously in 2013, a Mayo Clinic study assessed 119/1433 patients with MVI and observed an association with unfavorable prognostic characteristics, risk of metastasis and death from cancer in the univariate analysis, but in the multivariate analysis does not remain significant after being controlled with other prognostic variables established [27] .
